There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on US Physical Therapy (USPH – Research Report), Exact Sciences (EXAS – Research Report) and Maravai Lifesciences Holdings (MRVI – Research Report) with bullish sentiments.
US Physical Therapy (USPH)
In a report released today, Michael Petusky from Barrington maintained a Buy rating on US Physical Therapy, with a price target of $122.00. The company’s shares closed last Wednesday at $103.92.
According to TipRanks.com, Petusky is a 4-star analyst with an average return of
Currently, the analyst consensus on US Physical Therapy is a Strong Buy with an average price target of $120.00, representing a 16.9% upside. In a report released yesterday, Bank of America Securities also maintained a Buy rating on the stock with a $121.00 price target.
See today’s best-performing stocks on TipRanks >>
Exact Sciences (EXAS)
In a report released today, William Bonello from Craig-Hallum maintained a Buy rating on Exact Sciences, with a price target of $82.00. The company’s shares closed last Wednesday at $59.48, close to its 52-week low of $56.05.
According to TipRanks.com, Bonello is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Exact Sciences with a $99.00 average price target, representing a 62.3% upside. In a report issued on May 6, Leerink Partners also maintained a Buy rating on the stock with a $242.00 price target.
Maravai Lifesciences Holdings (MRVI)
In a report released today, Matt Hewitt from Craig-Hallum reiterated a Buy rating on Maravai Lifesciences Holdings, with a price target of $15.00. The company’s shares closed last Wednesday at $8.87.
According to TipRanks.com, Hewitt is a 1-star analyst with an average return of
Maravai Lifesciences Holdings has an analyst consensus of Strong Buy, with a price target consensus of $11.80, which is a 33.9% upside from current levels. In a report issued on April 29, RBC Capital also maintained a Buy rating on the stock with a $15.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on USPH:
- U.S. Physical Therapy raises FY24 adjusted EBITDA view to $82.5M-$87.5M
- U.S. Physical Therapy reports Q1 operating EPS 51c, consensus 56c
- Is USPH a Buy, Before Earnings?
- U.S. Physical Therapy acquires IIP services business, physical therapy practice
- U.S. Physical Therapy acquires 50% equity interest in PT practice for $16.4M
